129 related articles for article (PubMed ID: 2495219)
61. Glycaemic control, smoking habits and diabetes duration affect the extrinsic fibrinolytic system in type I diabetic patients but microangiopathy does not.
Nilsson TK; Lithner F
Acta Med Scand; 1988; 224(2):123-9. PubMed ID: 3138900
[TBL] [Abstract][Full Text] [Related]
62. Effects of lipoprotein(a) on in vitro lysis of whole blood thrombi from healthy volunteers.
Terres W; Krewitt M; Hamm CW
Thromb Res; 1993 Mar; 69(5):479-87. PubMed ID: 8497862
[TBL] [Abstract][Full Text] [Related]
63. Clinical significance of plasminogen activator inhibitor activity in patients with exercise-induced ischemia.
Sakata K; Kurata C; Taguchi T; Suzuki S; Kobayashi A; Yamazaki N; Rydzewski A; Takada Y; Takada A
Am Heart J; 1990 Oct; 120(4):831-8. PubMed ID: 2220535
[TBL] [Abstract][Full Text] [Related]
64. Hemostatic variables in Japanese and Caucasian men. Tissue plasminogen activator, antithrombin III, and protein C and their relations to coronary risk factors.
Iso H; Folsom AR; Wu KK; Finch A; Sato S; Munger RG; Shimamoto T; Terao A; Komachi Y
Am J Epidemiol; 1990 Jul; 132(1):41-6. PubMed ID: 2113352
[TBL] [Abstract][Full Text] [Related]
65. Detection of impaired fibrinolytic activity in coronary artery disease--electrophoretic and immuno-blotting analysis of tissue plasminogen activator.
Uno M; Tsuji H; Watanabe M; Takabuchi H; Kobayashi K; Shirai K; Sawada S; Toyoda T; Nakagawa M
Jpn Circ J; 1989 Mar; 53(3):229-36. PubMed ID: 2501532
[TBL] [Abstract][Full Text] [Related]
66. Plasma tissue factor pathway inhibitor levels in angiographically defined coronary artery disease among saudis.
Habib SS
Oman Med J; 2013 May; 28(3):191-4. PubMed ID: 23772285
[TBL] [Abstract][Full Text] [Related]
67. Prospective study of endogenous tissue plasminogen activator and risk of stroke.
Ridker PM; Hennekens CH; Stampfer MJ; Manson JE; Vaughan DE
Lancet; 1994 Apr; 343(8903):940-3. PubMed ID: 7909008
[TBL] [Abstract][Full Text] [Related]
68. Does smoking status influence the effect of physical exercise on fibrinolytic function in healthy volunteers?
Tello-Montoliu A; Roldán V; Climent VE; Sogorb F; Lip GY; Marín F
J Thromb Thrombolysis; 2006 Apr; 21(2):163-6. PubMed ID: 16622612
[TBL] [Abstract][Full Text] [Related]
69. Elevated tissue plasminogen activator antigen and stroke risk: The Stroke Prevention In Young Women Study.
Macko RF; Kittner SJ; Epstein A; Cox DK; Wozniak MA; Wityk RJ; Stern BJ; Sloan MA; Sherwin R; Price TR; McCarter RJ; Johnson CJ; Earley CJ; Buchholz DW; Stolley PD
Stroke; 1999 Jan; 30(1):7-11. PubMed ID: 9880380
[TBL] [Abstract][Full Text] [Related]
70. Plasma tissue plasminogen activator levels in patients with coronary heart disease.
Vandekerckhove Y; Baele G; De Puydt H; Weyne A; Clement D
Thromb Res; 1988 May; 50(3):449-53. PubMed ID: 3134744
[No Abstract] [Full Text] [Related]
71. Serum level of plasminogen activator inhibitor type-1 in addicted patients with coronary artery disease.
Forood A; Malekpour-Afshar R; Mahdavi A
Addict Health; 2014; 6(3-4):119-26. PubMed ID: 25984279
[TBL] [Abstract][Full Text] [Related]
72. Plasminogen and fibrinogen plasma levels in coronary artery disease.
Lima LM; Carvalho Md; Sousa Mde O
Rev Bras Hematol Hemoter; 2012; 34(4):298-301. PubMed ID: 23049444
[TBL] [Abstract][Full Text] [Related]
73. Plasma tissue-type plasminogen activator is associated with lipoprotein(a) and clinical outcomes in hospitalized patients with COVID-19.
Zhang Z; Dai W; Zhu W; Rodriguez M; Lund H; Xia Y; Chen Y; Rau M; Schneider EA; Graham MB; Jobe S; Wang D; Cui W; Wen R; Whiteheart SW; Wood JP; Silverstein R; Berger JS; Kreuziger LB; Barrett TJ; Zheng Z
Res Pract Thromb Haemost; 2023 Aug; 7(6):102164. PubMed ID: 37680312
[TBL] [Abstract][Full Text] [Related]
74. Serum lipoprotein(a), and plasminogen activator inhibitor-1 in uncomplicated type 2 diabetes mellitus: a case-control study.
Abdullah FE; Ahmed SN
Ann Med Surg (Lond); 2023 Aug; 85(8):3801-3805. PubMed ID: 37554894
[TBL] [Abstract][Full Text] [Related]
75. Evaluation of fibronectin, vitronectin, and leptin levels in coronary artery disease: impacts on thrombosis and thrombolysis.
Ekmekci H; Ekmekci OB; Sonmez H; Ozturk Z; Domanic N; Kokoglu E
Clin Appl Thromb Hemost; 2005 Jan; 11(1):63-70. PubMed ID: 15678274
[TBL] [Abstract][Full Text] [Related]
76. Soluble thrombomodulin as predictor of incident coronary heart disease.
Mennen LI; Amiral J; Guize L; Pujol Y; Scarabin PY
Lancet; 1999 Jul; 354(9176):425-6. PubMed ID: 10437897
[No Abstract] [Full Text] [Related]
77. The effect of modified electroconvulsive therapy on vasopressin release and haemostasis in man.
Hampton KK; Grant PJ; Boothby M; Dean HG; Davies JA; Prentice CR
Blood Coagul Fibrinolysis; 1990 Aug; 1(3):293-7. PubMed ID: 2129414
[TBL] [Abstract][Full Text] [Related]
78. Vascular plasminogen activator levels and thromboembolic disease in patients with gynecologic malignancies.
Gore M; Miller KE; Soong SJ; Clarke-Pearson DL; Pizzo SV
Am J Obstet Gynecol; 1984 Aug; 149(8):830-4. PubMed ID: 6540521
[TBL] [Abstract][Full Text] [Related]
79. Releasable vascular plasminogen activator and thrombotic strokes.
Pizzo SV; Petruska DB; Doman KA; Soong SJ; Fuchs HE
Am J Med; 1985 Oct; 79(4):407-11. PubMed ID: 3931468
[TBL] [Abstract][Full Text] [Related]
80. Nonlinear pharmacokinetics of tissue-type plasminogen activator in three animal species: a comparison of mathematical models.
Godfrey KR; Tanswell P; Bates RA; Chappell MJ; Madden FN
Biopharm Drug Dispos; 1998 Mar; 19(2):131-40. PubMed ID: 9533114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
